Esperion Files Pro Forma Financials for Corstasis Acquisition, Revealing Increased Pro Forma Loss
Summary
Esperion Therapeutics filed an amended 8-K to include audited financial statements for Corstasis Therapeutics and pro forma combined financials, detailing the financial impact of its recent $83.4 million acquisition, which shows an increased pro forma net loss.
Key Events
-
Acquisition Financials Disclosed
Esperion filed audited financial statements for Corstasis Therapeutics and unaudited pro forma combined financial statements for the year ended December 31, 2025, providing the financial details of the acquisition completed on April 2, 2026.
-
Acquisition Cost and Asset Valuation
The total cost of the Corstasis acquisition was $83.4 million, treated as an asset acquisition with no goodwill recognized. The primary asset acquired, the FDA-approved product Enbumyst, was valued at $77.1 million.
-
Acquisition Financing Details
The acquisition was funded by a $25.0 million term loan and a $50.0 million royalty purchase agreement, which includes an imputed yield of 1.3% per annum on the royalty sale.
-
Increased Pro Forma Net Loss
The pro forma combined statement of operations for 2025 shows a net loss of $(47.1) million, a significant increase compared to Esperion's historical net loss of $(22.7) million, reflecting the financial burden of the acquisition and its financing.
Analysis
This amended 8-K provides the detailed financial statements and pro forma financial information for Esperion's acquisition of Corstasis Therapeutics, which was completed on April 2, 2026. The filing quantifies the financial impact of the $83.4 million asset acquisition, including the financing structure and the pro forma effect on the company's balance sheet and statement of operations. The pro forma financials indicate a significant increase in net loss for the combined entity, primarily due to new interest expenses from the acquisition financing.
At the time of this filing, ESPR was trading at $3.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $811.7M. The 52-week trading range was $0.95 to $4.18. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.